1) These are not clinical biomarkers used for detection of cancer now, and in fact, they are known NOT to be clinical biomarkers useful for detecting cancer.
2) This is a publication focusing on the device/method, not the clinical application. It is published in a journal of vacuum science, not a cancer biology or medical journal.
3) There are several inaccurate things in the paper, one being that they state that current technology requires 1-2 weeks to measure either biomarker. Wrong, clinical tests exist today that can perform those immunoassays in minutes on large automated analyzers.
4) This isn't fraud, it's just a really typically overhyped report of a novel device/meausrement strategy (and it's not that novel) that targets a biomarker that has a role in cancer, and then some mass media picks it up and says that they have "the test for cancer". This happens all the time.
5) This should maybe be considered a proof of concept about the electronics of their detection strategy, since the immunoassay component is known (immunoassays to both biomarkers are not only published, but commercialized) and the clinical use of the biomarkers is not at all diagnostic for cancer or useful for screening.
1) These are not clinical biomarkers used for detection of cancer now, and in fact, they are known NOT to be clinical biomarkers useful for detecting cancer. 2) This is a publication focusing on the device/method, not the clinical application. It is published in a journal of vacuum science, not a cancer biology or medical journal. 3) There are several inaccurate things in the paper, one being that they state that current technology requires 1-2 weeks to measure either biomarker. Wrong, clinical tests exist today that can perform those immunoassays in minutes on large automated analyzers. 4) This isn't fraud, it's just a really typically overhyped report of a novel device/meausrement strategy (and it's not that novel) that targets a biomarker that has a role in cancer, and then some mass media picks it up and says that they have "the test for cancer". This happens all the time. 5) This should maybe be considered a proof of concept about the electronics of their detection strategy, since the immunoassay component is known (immunoassays to both biomarkers are not only published, but commercialized) and the clinical use of the biomarkers is not at all diagnostic for cancer or useful for screening.